Histone–Bromodomain protein interface (Histone–BRD interface)

The Histone–Bromodomain (BRD) protein interface is a fundamental epigenetic regulatory site where bromodomain-containing proteins recognize and bind to acetylated lysine residues on histone tails. This interaction serves as a 'reading' mechanism for the epigenetic code, facilitating the recruitment of transcriptional machinery and chromatin remodeling complexes to specific genomic loci (Filippakopoulos et al., Nature 2010). The Bromodomain and Extra-Terminal (BET) family, which includes BRD2, BRD3, and BRD4, are the most prominent proteins involved in this interface, playing pivotal roles in regulating the expression of genes associated with cell growth and survival (Shi and Vakoc, Mol Cell 2014). In many malignancies, such as Acute Myeloid Leukemia and NUT Midline Carcinoma, this interface is exploited to drive the constitutive overexpression of oncogenes like MYC (Doroshow et al., Nature Reviews Cancer 2017). Therapeutic strategies targeting this interface utilize small-molecule BET inhibitors that mimic acetyl-lysine, thereby competitively occupying the BRD binding pocket and displacing the protein from chromatin. This displacement leads to the rapid downregulation of pro-proliferative gene programs, making it a high-interest target for oncology, though its role in modulating inflammatory cytokines also suggests potential in treating autoimmune and cardiovascular conditions (Cochran et al., MedChemComm 2019).

Other names

Acetyl-lysine binding pocketBET bromodomain interfaceHistone-BRD interaction siteBromodomain-acetylated histone complex

Competitive inhibition of acetyl-lysine binding to the bromodomain pocket, leading to the displacement of BRD proteins from chromatin and subsequent suppression of downstream gene transcription.